Daphna Gelblum, MD
Radiation Oncology · Commack, NYNPI 1215917604
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $942 of the $1,068 with a category attached, or 88.2%. Merck accounts for 98.1% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2023 at $1,037 and has fallen 98.1% since, to $20 in 2024.
Across 7 payments — averaging $152.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- AstraZeneca$20
Across 44 payments — averaging $15,086 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$664K
What the payments were for
- Travel & lodging$94288%
- Food & beverage$11511%
- Education$111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 6 | $1,048 |
| AstraZeneca | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$942
How this compares
$1,068 in reported general payments places this provider in the 70th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 57 | $1,038 |
| Gabapentin | 20 | $615 |
| Sucralfate | 11 | $602 |
| Fluconazole | 20 | $486 |
| Pentoxifylline | 32 | $457 |
| Ondansetron Hcl | 15 | $375 |
| Lidocaine Hcl ViscousLidocaine Hcl | 15 | $367 |
| Fentanyl | 14 | $339 |
| Silver Sulfadiazine | 11 | $273 |
| Triamcinolone Acetonide | 17 | $218 |
| Dexamethasone | 15 | $189 |
| Omeprazole | 30 | $186 |
| Tramadol Hcl | 14 | $122 |
| Prednisone | 20 | $101 |
| Methylprednisolone | 11 | $84 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Commack
- Chung ChungSyracuse$3.1M
- Michael ZelefskyNew York$946K
- Jeffrey BogartSyracuse$772K
- Steven FinkelsteinSyracuse$578K
- Shawn ZimbergPlainview$411K
- Edward ObedianOyster Bay$391K
- Nancy LeeNew York$233K
- Dheerendra PrasadBuffalo$178K
- Robert SamsteinNew York$125K
- Jalal AhmedNew York$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.